Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 19/20 | 0.69 |
| ▸ | WDR77 | Q9BQA1 | 19/20 | 0.69 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29554787 | 0.93 | PRMT5 (0.68) | PRMT5WDR77HDAC1HDAC6 | |
| SCHEMBL29411068 | 0.85 | PRMT5 (0.63) | PRMT5WDR77HDAC1HDAC6 | |
| SCHEMBL29411043 | 0.82 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL20502058 | 0.82 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL30350902 | 0.81 | PRMT5 (0.79) | PRMT5WDR77 | |
| SCHEMBL16217320 | 0.81 | PRMT5 (0.79) | PRMT5WDR77 | |
| SCHEMBL16217337 | 0.81 | PRMT5 (0.79) | PRMT5WDR77 | |
| SCHEMBL30216806 | 0.81 | PRMT5 (0.79) | PRMT5WDR77 | |
| SCHEMBL16217324 | 0.81 | PRMT5 (0.79) | PRMT5WDR77 | |
| SCHEMBL29423950 | 0.81 | PRMT5 (0.69) | PRMT5WDR77HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3596073-B1 | TRICYCLIC COMPOUNDS FOR USE IN TREATMENT OF PROLIFERATIVE DISORDERS. | ARGONAUT THERAPEUTICS LTD (GB) | 2022-05-11 | — | — | EP | claimed |
| US-11274098-B2 | Tricyclic compounds for use in treatment of proliferative disorders | Argonaut Therapeutics Limited (GB) | 2022-03-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11274098-B2 | Tricyclic compounds for use in treatment of proliferative disorders | PRMT5, HDAC5, CDK15 | PRMT5 1/4885WDR77 123/4885HDAC1 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.